Comments for Dr. Karen Lee's Blog https://drkarenlee.ca An Inside Look at MS Research Mon, 09 Apr 2018 10:03:13 +0000 hourly 1 https://wordpress.org/?v=4.6.11 Comment on ACTRIMS 2018: What are some emerging concepts in MS? by Dawn https://drkarenlee.ca/actrims-2018-what-are-some-emerging-concepts-in-ms/#comment-584 Mon, 09 Apr 2018 10:03:13 +0000 https://drkarenlee.ca/?p=1687#comment-584 I am getting chemotherapy treatment for breast cancer and also have MS. My neurologist said that her patients getting chemo have had their MS symptoms reduced. Since 1 in 8 women get breast cancer and many of those get chemo and also have MS this might be a useful way to get participants to study. Just an idea. Thank you for your great blog.

]]>
Comment on Celebrating Brain Awareness Week by understanding Brain Health in MS by drkarenlee https://drkarenlee.ca/celebrating-brain-awareness-week-by-understanding-brain-health-in-ms/#comment-574 Mon, 26 Mar 2018 20:33:22 +0000 https://drkarenlee.ca/?p=1713#comment-574 Hi Carol,
I’m sorry to hear about this difficult time for you and your husband. I would recommend contacting our MS Navigators who will be able to assist you if you are looking to speak to a healthcare professional/support in the MS field. Connect with an MS navigator by calling 1-844-859-6789 or email msnavigators@mssociety.ca.

-Dr. K

]]>
Comment on International Women’s Day: Highlighting female scientists that are advancing research in MS by drkarenlee https://drkarenlee.ca/international-womens-day-highlighting-female-scientists-that-are-advancing-research-in-ms/#comment-573 Mon, 26 Mar 2018 20:30:15 +0000 https://drkarenlee.ca/?p=1701#comment-573 Hi Andrey,

Currently there is no cure for MS, rather medications that can help manage various aspects of the disease: underlying disease course (DMT), symptom management and general well-being strategies that are beneficial in all types of MS.
Ocrevus was approved for the treatment of early primary progressive MS (PPMS) in adults between the ages of 18 and 55 based on findings from the clinical trial ORATORIO. Early PPMS is defined by disease duration (length of time in years since diagnosis), and level of disability, in addition to magnetic resonance imaging (MRI) features characteristic of inflammation, indicating active disease. People outside of the age range of 18 to 55, or who have an EDSS score above 6.5 were not studied and as such the safety and efficacy of ocrelizumab is unknown. Health Canada is unable to provide authorization of a new drug (assess its safety and efficacy) without clinical trial data. Individuals interested in ocrelizumab but who are over the age of 55 are encouraged to speak to their neurologist.
Disease modifying therapies (DMT) target inflammation, so people with progressive MS who do not have inflammatory activity do not generally benefit from these therapies. People with progressive MS and their health care teams can do a great deal to manage the disease including rehabilitation and symptom management.
-Dr. K

]]>
Comment on Celebrating Brain Awareness Week by understanding Brain Health in MS by Carol Brons https://drkarenlee.ca/celebrating-brain-awareness-week-by-understanding-brain-health-in-ms/#comment-568 Sat, 17 Mar 2018 21:39:37 +0000 https://drkarenlee.ca/?p=1713#comment-568 My husband was diagnosed with MS 5 years ago. We live in Rural Saskatchewan and have limited access to neurologists. Although he has not had any active lesions since he was diagnosed and treated with steriods, I am disappointed that he has never seen a neurologist who specializes in MS and was only sent to the MS clinic once to discuss treatments.
He was using tecfidera for about 18 months but discontinued it due to an increase in side effects and is not using any MS meds at this time.
I feel there is not enough support for MS sufferers who are not in urban areas.

]]>
Comment on International Women’s Day: Highlighting female scientists that are advancing research in MS by Andrey https://drkarenlee.ca/international-womens-day-highlighting-female-scientists-that-are-advancing-research-in-ms/#comment-562 Fri, 09 Mar 2018 10:46:28 +0000 https://drkarenlee.ca/?p=1701#comment-562 Very interesting. Dear Dr. Karen Lee, I am suffering from PPMS. I was diagnosed in 2011. Now I move with walkers. There has been no cure for PPMS until recently. Health Canada approved OCREVUS on February, the 15th, 2018 as a cure for early PPMS. As far as I understand, OVREVUS can slow progression of PPMS in future? I don’t think that my PPMS is early. What to do in my case to overcome my PPMS? May be it’s a remyelination? What to do with my existing disability?

]]>
Comment on ACTRIMS 2018: What are some emerging concepts in MS? by Will https://drkarenlee.ca/actrims-2018-what-are-some-emerging-concepts-in-ms/#comment-560 Wed, 28 Feb 2018 15:25:44 +0000 https://drkarenlee.ca/?p=1687#comment-560 Chris, any chance I could reach out…in the early stages of planning for Moscow myself. Would love to get yours or your daughters perspective on the entire process. Cheers.

]]>
Comment on ACTRIMS 2018: Cutting Edge Development in MS Research by SANDRA MAE WATTS https://drkarenlee.ca/actrims-2018-cutting-edge-development-in-ms-research/#comment-558 Sun, 04 Feb 2018 10:42:21 +0000 https://drkarenlee.ca/?p=1694#comment-558 A therapy 2 promote remyelination in MS! Since anti lingo 2 was not 100% successful.

Is anything happening on the MS acquired nystagmus front?

]]>
Comment on ACTRIMS 2018: What are some emerging concepts in MS? by Chris Chatten https://drkarenlee.ca/actrims-2018-what-are-some-emerging-concepts-in-ms/#comment-557 Sun, 04 Feb 2018 07:00:14 +0000 https://drkarenlee.ca/?p=1687#comment-557 Hi Dr Lee
Thanks for your response. We went to Moscow with our daughter who had the treatment. Dr Fedorenko has performed roughly 900 transplants, it may be beneficial to google him and the Pirgov hospital for further information. There are blogs on FB with many experiences of people at all stages of MS who have had the treatment, the success rate is high.
It seems that funding would have to come from government as there is no benefit for the pharmaceutical companies to pursue this direction.
Let’s hope things improve for the hundreds of thousands of people suffering.

]]>
Comment on ACTRIMS 2018: What are some emerging concepts in MS? by drkarenlee https://drkarenlee.ca/actrims-2018-what-are-some-emerging-concepts-in-ms/#comment-556 Sat, 03 Feb 2018 17:35:50 +0000 https://drkarenlee.ca/?p=1687#comment-556 Hi Chris,

Thanks for your question and comment. The HSCT is still a hot topic at MS conferences, however, as many of the HSCT trials in MS have been completed and have been effective is slowing or stopping disease progression, the question commonly addressed at the conference is the mechanisms through how this therapy works. The MS Society of Canada and MS Scientific Research Foundation funded a clinical trial involving HSC transplants, led by Drs. Mark Freedman and Harry Atkins from the Ottawa Hospital Research Institute. For more information see Canadian Bone Marrow Transplantation (BMT) Trial. This trial was completed and published in 2016 in Lancet. Due to the serious side effects associated with chemotherapy, only those individuals who had aggressive, highly inflammatory relapsing-remitting MS (RRMS) were part of the trial. As this therapy is only for those with aggressive forms of RRMS, the MS Society of Canada is supporting the MESCAMS (MEsenchymal Stem cell therapy for CAnadian MS patients), a phase II clinical trial. One major factor which distinguishes this study from the previously conducted Canadian bone marrow transplantation (BMT) trial is that participants are not subjected to intensive chemotherapy, which is required prior to BMT to effectively eliminate the diseased immune system. For more information on this clinical trial, check out our website. So Canada is one of the leaders in this area and the MS Society of Canada is proud to support this effort.
-Dr. K

]]>
Comment on ACTRIMS 2018: What are some emerging concepts in MS? by Chris Chatten https://drkarenlee.ca/actrims-2018-what-are-some-emerging-concepts-in-ms/#comment-555 Sat, 03 Feb 2018 17:03:32 +0000 https://drkarenlee.ca/?p=1687#comment-555 I would like to hear more about HSCT, I believe this to be a potential standard of care for MS in the future yet I don’t see much information coming from conferences etc.
Mexico and Russia seem to be leading the field in this area, why are we lagging behind in this field?

]]>